Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-08-19
    E.g., 2018-08-19

Archive Search

Pages

208 results
5:46 PM, Aug 03, 2018  |  BioCentury | Finance

Functions of formulation

Recombinant human α 1-antitrypsin $9 $54 $63 11% 06/06/11 ViroPharma Inc. (B) 1 Inflammation Subcutaneous Cinryze
1:02 PM, Mar 02, 2018  |  BC Week In Review | Clinical News  |  Regulatory

Priority review for Shire's HAE prophylactic

a portfolio of HAE drugs that meet different patient needs. Among them is prophylactic treatment Cinryze
four days. Lanadelumab, which is dosed every two weeks, could provide a dosing benefit over Cinryze
2:09 PM, Feb 23, 2018  |  BC Extra | Company News

Priority Review for Shire's HAE prophylactic

a portfolio of HAE drugs that meet different patient needs. Among them is prophylactic treatment Cinryze
four days. Lanadelumab, which is dosed every two weeks, could provide a dosing benefit over Cinryze
6:03 PM, Jan 26, 2018  |  BioCentury | Finance

All together now

Shire plc (LSE:SHP; NASDAQ:SHPG) acquired in 2014 for $4.2 billion to obtain ViroPharma’s HAE prophylactic Cinryze
12:55 PM, Oct 13, 2017  |  BioCentury | Regulation

Expanding the HAE tool kit

six new drugs have been approved to treat or prevent HAE attacks. The prophylactic treatments Cinryze
from Shire plc and Haegarda from CSL Ltd. have reduced the frequency of attacks. Cinryze has …
would help me live as if I didn’t have HAE at all.” Unidentified HAE patient Cinryze
12:16 PM, Sep 15, 2017  |  BC Week In Review | Clinical News  |  Clinical Results

Shire's subcutaneous HAE candidate meets in Phase III

SHP616 consecutively for 28 weeks. SHP616 is a lower-dose volume, subcutaneous liquid formulation of IV Cinryze
an IV therapy, or who have had complications of indwelling central catheters. Shire markets IV Cinryze
3:33 PM, Sep 11, 2017  |  BC Extra | Clinical News

Shire’s subcutaneous HAE candidate meets in Phase III

patients ages 12 and older. SHP616 is a lower-dose volume, subcutaneous liquid formulation of IV Cinryze
an IV therapy, or who have had complications of indwelling central catheters. Shire markets IV Cinryze
the U.S. and EU for routine prophylaxis of HAE attacks in adolescent and adult patients. Cinryze
12:28 PM, May 18, 2017  |  BC Extra | Clinical News

Shire HAE treatment from Dyax deal clears Phase III hurdle

Firazyr icatibant, a self-administered therapy to treat acute attacks in patients aged 18 and older; Cinryze
2:45 PM, May 12, 2017  |  BioCentury | Strategy

Vertical vision

markets Firazyr icatibant, a self-administered therapy to treat acute attacks in patients 18 and up; Cinryze
4:50 PM, Dec 19, 2016  |  BC Week In Review | Clinical News  |  Regulatory

Cinryze regulatory update

EMA’s CHMP recommended expanding the label of Cinryze from Shire for treatment and pre-procedure prevention of …
for routine prevention of attacks to include children ages 6-11 with severe and recurrent HAE. Cinryze
angioedema attacks in adults and adolescents with HAE. Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland  Product: Cinryze

Pages